ANG and acute kidney injury: The exogenous administration of Ang-(1-7) is also an option and it is especially appealing in patients with severe COVID-19 disease, given the high incidence of AKI [95] in this ACE2-depleted disorder [4,5], and such clinical trials are currently under way [22,96].